August 24, 2016
A California federal judge on Tuesday tossed a shareholder suit accusing specialty pharmaceutical company MannKind Corp. of issuing false or misleading statements in connection with poor sales of its lone product, a diabetes drug, saying investors failed to prove the company did so.